



# Culture-Independent Detection of Nontuberculous Mycobacteria in Clinical Respiratory Samples

Gianny P. Scoleri,<sup>a</sup> Jocelyn M. Choo,<sup>a</sup> Lex E. X. Leong,<sup>a</sup> Thomas R. Goddard,<sup>b</sup> Lisa Shephard,<sup>c</sup> Lucy D. Burr,<sup>d,e</sup> Ivan Bastian,<sup>c</sup> Rachel M. Thomson,<sup>f</sup> Geraint B. Rogers<sup>a</sup>

SAHMRI Infection and Immunity Theme, School of Medicine, Flinders University, Adelaide, South Australia, Australia<sup>a</sup>; Department of Respiratory and Medicine, WCH, and Paediatrics and Reproductive Health, School of Medicine, University of Adelaide, Australia<sup>b</sup>; Microbiology Infectious Diseases Directorate, SA Pathology, Adelaide, South Australia<sup>c</sup>; Immunity, Infection and Inflammation Program, Mater Research Institute, University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia<sup>d</sup>; Department of Respiratory Medicine, Mater Health Services, South Brisbane, QLD, Australia<sup>e</sup>; Gallipoli Medical Research Centre, Greenslopes Private Hospital and University of Queensland, Brisbane, Queensland, Australia<sup>f</sup>

**Culture-based detection of nontuberculous *Mycobacteria* (NTM) in respiratory samples is time consuming and can be subject to overgrowth by nonmycobacterial bacteria. We describe a single-reaction TaqMan quantitative PCR assay for the direct detection of NTM species in clinical samples that is specific, sensitive, and robust.**

While rates of infection caused by members of the *Mycobacterium tuberculosis* complex continue to fall in developed countries (1, 2), disease caused by nontuberculous mycobacteria (NTM) is an area of growing concern (3–6). Pulmonary infection represents more than 90% of NTM cases (7) and has been described in a range of clinical contexts (8–11). Appropriate management of suspected pulmonary NTM infection requires the timely detection and identification of the etiological agent. The current “gold standard” for detection of NTM in respiratory samples relies on protracted *in vitro* culture, potentially delaying targeted therapy. It also requires samples to undergo decontamination prior to culture to lower levels of commensal microbiota (12) and is associated with variable sensitivity (13). The ability to perform a rapid quantitative screen for the presence of any NTM species would provide an important early indication of mycobacterial involvement and would be informative in cases where samples are culture negative, despite clinical or radiological signs.

To prevent false-positive results arising from the detection of closely related species (14, 15), existing molecular assays target narrow phylogenetic groups or specific pathogens (16–21), require prior mycobacterial isolation by culture (22–24), or are unable to provide accurate species-level NTM identification (25). We describe a TaqMan quantitative PCR (qPCR) assay, based on the single-copy *hsp65* gene, for the direct detection of NTM species in respiratory clinical samples.

The assay design was based on the full-length *hsp65* gene sequences that are available for 116 of the 174 currently described NTM species, including all 56 NTM species reported in respiratory disease (see Fig. S1 in the supplemental material). The PCR primers (forward, HSP171 [5′-CGCCAAGGAGATCGAGCTGG-3′], and reverse, HSP563 [5′-GGACAAGGTCTGGCAACGAGGG-3′]) generate a 348-bp *hsp65* amplicon and are used in conjunction with a TaqMan probe (5′-FAM-AGAAGGCCGTCGAGAAGGTCA-BHQ-3′ [FAM, 6-carboxyfluorescein; BHQ, black hole quencher]) at an annealing temperature of 60°C (Fig. 1). A detailed description of assay development and methods is provided in the supplemental material.

*In silico* analysis indicated complete homology to the targeted *hsp65* gene region for 77 *Mycobacterium* species. Fourteen species had ≤2 nucleotide mismatches within the primer binding region, with a corresponding reduction in annealing temperature

of up to 4.5°C. However, in all such cases, the corresponding primer binding region showed 100% sequence homology (see Tables S1 and S2 in the supplemental material). Twenty-one mycobacterial species (including *M. tuberculosis* and *Mycobacterium leprae*) and 40 assessed nonmycobacterial species had >3 nucleotide mismatches to the primer sequences, requiring an annealing temperature of <55.5°C (see Fig. S2 and Table S3 in the supplemental material).

The assay’s performance was assessed using DNA extracts from 15 NTM strains and negative controls that included closely related nonmycobacterial species, common respiratory pathogens, nine *M. tuberculosis* strains, *Mycobacterium bovis*, *Escherichia coli*, and human DNA (Table 1). The assay’s sensitivity was assessed using a dilution series of purified *Mycobacterium abscessus* DNA (selected based both on its clinical importance and its position within NTM phylogeny). The correlation between template concentration and cycle threshold ( $C_T$ ) values was linear between  $3.34 \times 10^3$  and  $2.65 \times 10^8$  CFU/ml equivalents (slope,  $-3.31$ ;  $R^2 = 0.99$ ), with a reaction efficiency of 100%. Analysis using *Mycobacterium intracellulare* DNA, a species with a single-base primer mismatch, resulted in a linear range of  $6.26 \times 10^3$  to  $4.39 \times 10^8$  CFU/ml equivalents (slope,  $-3.403$ ;  $R^2 = 0.99$ ), with a reaction efficiency of 97%.

The potential for carryover of clinical sample components to influence assay performance was assessed in three ways. First, the amplification efficiency and dynamic range of *M. abscessus* DNA were determined following the addition of DNA extracts from

Received 29 June 2016 Returned for modification 2 July 2016

Accepted 6 July 2016

Accepted manuscript posted online 13 July 2016

**Citation** Scoleri GP, Choo JM, Leong LEX, Goddard TR, Shephard L, Burr LD, Bastian I, Thomson RM, Rogers GB. 2016. Culture-independent detection of nontuberculous mycobacteria in clinical respiratory samples. *J Clin Microbiol* 54:2395–2398. doi:10.1128/JCM.01410-16.

**Editor:** G. A. Land, Carter BloodCare & Baylor University Medical Center

Address correspondence to Geraint B. Rogers, [geraint.rogers@sahmri.com](mailto:geraint.rogers@sahmri.com).

Supplemental material for this article may be found at <http://dx.doi.org/10.1128/JCM.01410-16>.

Copyright © 2016, American Society for Microbiology. All Rights Reserved.




FIG 1 Primer and probe target sites. Primer binding sites for previously described NTM detection assay primers are also shown, as follows: #1, Telenti et al. (30); #2, Kim et al. (31).

culture- and qPCR-negative bronchoalveolar lavage (BAL) and sputum samples. Second, the assay's performance was assessed following the addition of purified human DNA at a concentration that substantially exceeded the levels in respiratory clinical sam-

ples. Third, the impact of the addition of horse blood prior to DNA extraction on *M. abscessus* DNA amplification efficiency was assessed, using a dilution series starting at 50% (vol/vol). In each case, no significant change in assay performance was observed

TABLE 1 Amplification data for reference and control strains

Species (strain)	Source <sup>c</sup>	$C_T$ value	CFU/ml equivalent
<b>Mycobacterial species<sup>a</sup></b>			
<i>M. abscessus</i>	ATCC 19977	16.9	$2.65 \times 10^8$
<i>M. avium</i>	Clinical strain	20.1	$7.56 \times 10^7$
<i>M. chelonae</i>	ATCC 35752	22.6	$1.26 \times 10^7$
<i>M. flavescens</i>	Collection strain	28.3	$2.42 \times 10^5$
<i>M. fortuitum</i>	ATCC 9820	18.6	$2.08 \times 10^8$
<i>M. goodii</i>	Clinical strain	21.3	$3.21 \times 10^7$
<i>M. gordonae</i>	Clinical strain	23	$9.93 \times 10^6$
<i>M. interjectum</i>	Clinical strain	21.2	$3.34 \times 10^7$
<i>M. intracellulare</i>	Clinical strain	23	$9.99 \times 10^6$
<i>M. kansasii</i>	Clinical strain	24.9	$2.68 \times 10^6$
<i>M. lentiflavum</i>	Clinical strain	21	$3.81 \times 10^7$
<i>M. marinum</i>	Collection strain	23.3	$7.72 \times 10^6$
<i>M. simiae</i>	Clinical strain	19	$1.62 \times 10^8$
<i>M. smegmatis</i>	Clinical strain	20.8	$4.39 \times 10^7$
<i>M. bovis</i> (BCG)	Collection strain	ND <sup>d</sup>	ND
<i>M. tuberculosis</i> (H37Rv)	Clinical strain	ND	ND
<i>M. tuberculosis</i> (Uganda 1)	Clinical strain	ND	ND
<i>M. tuberculosis</i> (Orygis)	Clinical strain	ND	ND
<i>M. tuberculosis</i> (MDR)	Clinical strain	ND	ND
<i>M. tuberculosis</i> (LAM/Uganda 1)	Clinical strain	ND	ND
<i>M. tuberculosis</i> (EAI)	Clinical strain	ND	ND
<i>M. tuberculosis</i> (EAI 1)	Clinical strain	ND	ND
<i>M. tuberculosis</i> (BJ Delhi CAS)	Clinical strain	ND	ND
<i>M. tuberculosis</i> (BJ Delhi CAS 1)	Clinical strain	ND	ND
<b>Nonmycobacterial species<sup>b</sup></b>			
<i>Rhodococcus equi</i>	Collection strain	ND	ND
<i>Nocardia farcinica</i>	Collection strain	ND	ND
<i>Corynebacterium glucuronolyticum</i>	Collection strain	ND	ND
<i>Staphylococcus aureus</i>	Clinical strain	ND	ND
<i>Pseudomonas aeruginosa</i>	Clinical strain	ND	ND
<i>Haemophilus influenzae</i>	Clinical strain	ND	ND
<i>Escherichia coli</i>	Clinical strain	ND	ND
<i>Streptococcus pneumoniae</i>	Clinical strain	ND	ND
Human	Placental DNA	ND	ND

<sup>a</sup> South Australian pathology collection.

<sup>b</sup> Flinders Medical Centre pathology laboratory.

<sup>c</sup> ATCC, American Type Culture Collection.

<sup>d</sup> ND, not detected.

TABLE 2 NTM-positive respiratory samples as determined by qPCR, and corresponding diagnostic culture results

Sample type	$C_T$ value	CFU/ml equivalent	Identification obtained with:	
			qPCR/sequencing	Diagnostic microbiology
BAL fluid	30.5	$1.36 \times 10^5$	<i>M. avium</i>	<i>M. avium</i>
BAL fluid	30.9	$1.02 \times 10^5$	<i>M. avium</i>	<i>M. avium</i>
BAL fluid	32.1	$4.58 \times 10^4$	<i>M. intracellulare</i>	<i>M. intracellulare</i>
BAL fluid	35.4	$1.13 \times 10^4$	<i>M. avium</i>	<i>M. avium</i>
BAL fluid	34	$8.70 \times 10^4$	<i>M. avium</i>	— <sup>a</sup>
BAL fluid	32.7	$3.02 \times 10^4$	<i>M. avium</i>	<i>M. avium</i>
Sputum	31.1	$3.22 \times 10^4$	<i>M. massiliense</i>	<i>M. massiliense</i>
Sputum	31.7	$2.08 \times 10^4$	<i>M. flavescens</i>	— <sup>a,b</sup>
Sputum	31.5	$2.44 \times 10^4$	<i>M. abscessus</i>	<i>M. abscessus</i>
Sputum	33.4	$6.43 \times 10^3$	<i>M. avium</i>	— <sup>a</sup>
Sputum	35.5	$1.49 \times 10^3$	<i>M. avium</i>	<i>M. avium</i>

<sup>a</sup> —, not detected.

<sup>b</sup> Sample was recorded as “insufficient for adequate assessment” for standard diagnostic analysis.

(Mann Whitney test,  $P > 0.3$ ) (see Fig. S3 to S5 in the supplemental material).

Assay validation was performed using 42 respiratory samples from patients suspected of respiratory NTM infection, including 30 BAL samples and 12 sputum samples (of which 8 were NTM positive according to standard diagnostic testing; see Table S4 in the supplemental material). Positive results from NTM culture were confirmed by qPCR, and species identity was confirmed by DNA sequencing. However, in three cases, samples were NTM culture negative but qPCR positive. *Mycobacterium avium* was detected in the BAL sample at a concentration of  $8.7 \times 10^4$  CFU/ml equivalents, while *Mycobacterium flavescens* and *M. avium* were detected in the two sputum samples at  $2.1 \times 10^4$  and  $6.4 \times 10^3$  CFU/ml equivalents, respectively (Table 2; see also Table S5).

Negative culture results in patients with suspected NTM infection are not uncommon, with NTM isolated from subsequent samples in some instances (26). A number of factors could contribute to discrepancies between culture-dependent and molecular analysis. For example, culture overgrowth by nonmycobacterial species can substantially reduce NTM detection, while sample decontamination techniques used to prevent this can reduce mycobacterial viability (12). In addition, NTM recovery can be reduced in patients receiving commonly used antibiotics, such as macrolides and quinolones (12).

In the case of the culture-negative, qPCR-positive BAL sample, high levels of *Haemophilus influenzae* growth were reported. While this species is fastidious, the finding suggests the potential presence of other nonmycobacterial species that might have contributed to the failure to isolate NTM through bacterial overgrowth. In the case of the culture-negative sputum sample in which *M. flavescens* was detected by PCR, *M. abscessus* had been isolated from this patient on a previous occasion (although definitive typing had not been performed), and the patient had received apparently successful eradication therapy. While the basis for discordance remains unclear, it is important to highlight that, as with all PCR-based assays, a positive result does not rely on the presence of viable bacterial cells (27, 28). DNA in nonviable bacteria or present in the extracellular environment (as might occur follow-

ing successful antibiotic therapy) can also act as a PCR template (29), a factor that must be taken into account when interpreting disparities between culture and PCR-based results. In the case of the patient in whose sample *M. avium* was detected by qPCR alone, the corresponding sample was recorded as being “insufficient for adequate assessment” by culture (an outcome that is sometimes interpreted wrongly at the clinical level as a culture-negative result). However, sputum samples collected both prior to and following this sample were also found to be culture negative, suggesting a genuine discrepancy between culture and qPCR results.

Our study was unable to assess the assay’s ability to detect a number of rare or recently described NTM species for which high-quality DNA sequence data are not yet available. It was further limited by a requirement for DNA sequencing to identify the source of positive PCR results, a technology that is not available in all laboratories. However, the single-reaction qPCR assay described offers substantial advantages over other molecular assays in terms of time and cost. Importantly, the assay does not amplify DNA from *M. tuberculosis*, a range of closely related nonmycobacterial species, or common airway bacteria and is unaffected by the presence of high concentrations of human DNA or blood derivatives. Our assay provides a specific, sensitive, and robust means to rapidly screen respiratory clinical samples for the presence of NTM and represents an important adjunct to conventional diagnostic approaches.

#### ACKNOWLEDGMENTS

We are grateful to David Gordon, Microbiology and Infectious Diseases, Flinders Medical Centre, who provided clinical isolates and bacterial type strains.

The authors declare no conflict of interest.

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

#### FUNDING INFORMATION

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit-sectors.

#### REFERENCES

1. Brode SK, Daley CL, Marras TK. 2014. The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: a systematic review. *Int J Tuberc Lung Dis* 18:1370–1377. <http://dx.doi.org/10.5588/ijtld.14.0120>.
2. World Health Organization. 2015. Leprosy. Fact sheet N101. WHO, Geneva, Switzerland. <http://www.who.int/mediacentre/factsheets/fs101/en/>. Accessed 3 May 2016.
3. Marras TK, Chedore P, Ying AM, Jamieson F. 2007. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997–2003. *Thorax* 62:661–666. <http://dx.doi.org/10.1136/thx.2006.070797>.
4. Martín-Casabona N, Bahrmand AR, Bennedsen J, Thomsen VO, Curcio M, Fauville-Dufaux M, Feldman K, Havelkova M, Katila ML, Köksalan K, Pereira MF, Rodrigues F, Pfyffer GE, Portaels F, Urgell JR, Rüsç-Gerdes S, Tortoli E, Vincent V, Watt B, Spanish Group for Non-Tuberculosis Mycobacteria. 2004. Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. *Int J Tuberc Lung Dis* 8:1186–1193.
5. Mirsaeidi M, Machado RF, Garcia JG, Schraufnagel DE. 2014. Nontuberculous mycobacterial disease mortality in the United States, 1999–2010: a population-based comparative study. *PLoS One* 9:e91879. <http://dx.doi.org/10.1371/journal.pone.0091879>.
6. Thomson RM, NTM working group at Queensland TB Control Centre and Queensland Mycobacterial Reference Laboratory. 2010. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. *Emerg Infect Dis* 16:1576–1583. <http://dx.doi.org/10.3201/eid1610.091201>.

7. O'Brien RJ, Geiter LJ, Snider DE, Jr. 1987. The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey. *Am Rev Respir Dis* 135:1007–1014.
8. Horsburgh CR, Jr, Gettings J, Alexander LN, Lennox JL. 2001. Disseminated *Mycobacterium avium* complex disease among patients infected with human immunodeficiency virus, 1985–2000. *Clin Infect Dis* 33:1938–1943. <http://dx.doi.org/10.1086/324508>.
9. Park IK, Olivier KN. 2015. Nontuberculous mycobacteria in cystic fibrosis and non-cystic fibrosis bronchiectasis. *Semin Respir Crit Care Med* 36:217–224. <http://dx.doi.org/10.1055/s-0035-1546751>.
10. Prince DS, Peterson DD, Steiner RM, Gottlieb JE, Scott R, Israel HL, Figueroa WG, Fish JE. 1989. Infection with *Mycobacterium avium* complex in patients without predisposing conditions. *N Engl J Med* 321:863–868. <http://dx.doi.org/10.1056/NEJM198909283211304>.
11. Winthrop KL, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M, Saulson A, Hedberg K. 2010. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. *Am J Respir Crit Care Med* 182:977–982. <http://dx.doi.org/10.1164/rccm.201003-0503OC>.
12. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Jr, Winthrop K, ATS Mycobacterial Diseases Subcommittee, American Thoracic Society, Infectious Diseases Society of America. 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med* 175:367–416. <http://dx.doi.org/10.1164/rccm.200604-571ST>.
13. van Ingen J. 2015. Microbiological diagnosis of nontuberculous mycobacterial pulmonary disease. *Clin Chest Med* 36:43–54. <http://dx.doi.org/10.1016/j.ccm.2014.11.005>.
14. Dai J, Chen Y, Dean S, Morris JG, Salfinger M, Johnson JA. 2011. Multiple-genome comparison reveals new loci for *Mycobacterium* species identification. *J Clin Microbiol* 49:144–153. <http://dx.doi.org/10.1128/JCM.00957-10>.
15. Radomski N, Lucas FS, Moilleron R, Cambau E, Haenn S, Moulin L. 2010. Development of a real-time qPCR method for detection and enumeration of *Mycobacterium* spp. in surface water. *Appl Environ Microbiol* 76:7348–7351. <http://dx.doi.org/10.1128/AEM.00942-10>.
16. Foongladda S, Pholwat S, Eampokalap B, Kiratisin P, Sutthent R. 2009. Multi-probe real-time PCR identification of common *Mycobacterium* species in blood culture broth. *J Mol Diagn* 11:42–48. <http://dx.doi.org/10.2353/jmoldx.2009.080081>.
17. Leung KL, Yip CW, Cheung WF, Lo AC, Ko WM, Kam KM. 2009. Development of a simple and low-cost real-time PCR method for the identification of commonly encountered mycobacteria in a high throughput laboratory. *J Appl Microbiol* 107:1433–1439. <http://dx.doi.org/10.1111/j.1365-2672.2009.04324.x>.
18. Lim SY, Kim BJ, Lee MK, Kim K. 2008. Development of a real-time PCR-based method for rapid differential identification of *Mycobacterium* species. *Lett Appl Microbiol* 46:101–106. <http://dx.doi.org/10.1111/j.1472-765X.2007.02278.x>.
19. Ngan GJ, Ng LM, Jureen R, Lin RT, Teo JW. 2011. Development of multiplex PCR assays based on the 16S-23S rRNA internal transcribed spacer for the detection of clinically relevant nontuberculous mycobacteria. *Lett Appl Microbiol* 52:546–554. <http://dx.doi.org/10.1111/j.1472-765X.2011.03045.x>.
20. Richardson ET, Samson D, Banaei N. 2009. Rapid identification of *Mycobacterium tuberculosis* and nontuberculous mycobacteria by multiplex, real-time PCR. *J Clin Microbiol* 47:1497–1502. <http://dx.doi.org/10.1128/JCM.01868-08>.
21. Gopinath K, Singh S. 2009. Multiplex PCR assay for simultaneous detection and differentiation of *Mycobacterium tuberculosis*, *Mycobacterium avium* complexes and other *Mycobacterium* species directly from clinical specimens. *J Appl Microbiol* 107:425–435. <http://dx.doi.org/10.1111/j.1365-2672.2009.04218.x>.
22. Kim JU, Cha CH, An HK. 2015. Direct identification of mycobacteria from clinical specimens by multiplex real-time PCR. *J Appl Microbiol* 118:1498–1506. <http://dx.doi.org/10.1111/jam.12780>.
23. Kim K, Lee H, Lee MK, Lee SA, Shim TS, Lim SY, Koh WJ, Yim JJ, Munkhtsetseg B, Kim W, Chung SI, Kook YH, Kim BJ. 2010. Development and application of multiprobe real-time PCR method targeting the hsp65 gene for differentiation of *Mycobacterium* species from isolates and sputum specimens. *J Clin Microbiol* 48:3073–3080. <http://dx.doi.org/10.1128/JCM.00939-10>.
24. Tran AC, Halse TA, Escuyer VE, Musser KA. 2014. Detection of *Mycobacterium avium* complex DNA directly in clinical respiratory specimens: opportunities for improved turn-around time and cost savings. *Diagn Microbiol Infect Dis* 79:43–48. <http://dx.doi.org/10.1016/j.diagmicrobio.2014.01.019>.
25. Perry MD, White PL, Ruddy M. 2014. Potential for use of the Seegene Anyplex MTB/NTM real-time detection assay in a regional reference laboratory. *J Clin Microbiol* 52:1708–1710. <http://dx.doi.org/10.1128/JCM.03585-13>.
26. Jarand J, Davis JP, Cowie RL, Field SK, Fisher DA. 2016. Long-term follow-up of *Mycobacterium avium* complex lung disease in patients treated with regimens including clofazimine and/or rifampin. *Chest* 149:1285–1293. <http://dx.doi.org/10.1378/chest.15-0543>.
27. Rogers GB, Stressmann FA, Koller G, Daniels T, Carroll MP, Bruce KD. 2008. Assessing the diagnostic importance of nonviable bacterial cells in respiratory infections. *Diagn Microbiol Infect Dis* 62:133–141. <http://dx.doi.org/10.1016/j.diagmicrobio.2008.06.011>.
28. Kennedy N, Gillespie SH, Saruni AO, Kisyombe G, McNerney R, Ngowi FI, Wilson S. 1994. Polymerase chain reaction for assessing treatment response in patients with pulmonary tuberculosis. *J Infect Dis* 170:713–716. <http://dx.doi.org/10.1093/infdis/170.3.713>.
29. Rogers GB, Marsh P, Stressmann AF, Allen CE, Daniels TV, Carroll MP, Bruce KD. 2010. The exclusion of dead bacterial cells is essential for accurate molecular analysis of clinical samples. *Clin Microbiol Infect* 16:1656–1658. <http://dx.doi.org/10.1111/j.1469-0691.2010.03189.x>.
30. Telenti A, Marchesi F, Balz MM, Bally F, Bottger EC, Bodmer T. 1993. Rapid identification of *Mycobacteria* to the species level by polymerase chain reaction and restriction enzyme analysis. *J Clin Microbiol* 31:175–178.
31. Kim H, Kim SH, Shim TS, Kim MN, Bai GH, Park YG, Lee SH, Chae GT, Cha CY, Kook YH, Kim BJ. 2005. Differentiation of *Mycobacterium* species by analysis of the heat-shock protein 65 gene (hsp65). *Int J Syst Evol Microbiol* 55:1649–1656. <http://dx.doi.org/10.1099/ijso.0.63553-0>.